The Ipsen Group Publishes Its 2012 Registration Document

  The Ipsen Group Publishes Its 2012 Registration Document

Business Wire

PARIS -- March 27, 2013

Regulatory News :

Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) announced today that its 2012
Registration Document has been filed with the French “Autorité des Marchés
Financiers (AMF)” on 26 March 2013 and registered under the number D.13-0219.

The document is available on the Company’s website: and on the
AMF’s website: Copies are also available at Ipsen’s
headquarters – 65 quai Georges Gorse, 92650 Boulogne-Billancourt cedex –

The following documents are incorporated into the 2012 Registration Document:

  *The Annual Financial Report;
  *The Chairman’s Report on the preparation and organisation of the works of
    the Board of Directors and internal control procedures and risk management
    procedures  and the corresponding Statutory Auditor’s report;
  *The information relating to the fees paid to the Statutory Auditors.

About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales
exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in
specialty healthcare solutions for targeted debilitating diseases. Its
development strategy is supported by 3 franchises: neurology, endocrinology
and uro-oncology. Moreover, the Group has an active policy of partnerships.
Ipsen's R&D is focused on its innovative and differentiated technological
platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250
million, representing more than 20% of Group sales. The Group has close to
4,900 employees worldwide. Ipsen’s shares are traded on segment A of Euronext
Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service
de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen
has implemented a Sponsored Level I American Depositary Receipt (ADR) program,
which trade on the over-the-counter market in the United States under the
symbol IPSEY. For more information on Ipsen, visit


Didier Véron
Vice President, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
Brigitte Le Guennec
Media and Public Relations Officer
Tel.: +33 (0)1 58 33 51 17
Fax: +33 (0)1 58 33 50 58
E-mail :
Financial Community
Pierre Kemula
Vice President, Corporate Finance, Treasury and Financial Markets
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
Stéphane Durant des Aulnois
Investor Relations Manager
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63
Press spacebar to pause and continue. Press esc to stop.